{"DataElement":{"publicId":"2738448","version":"3","preferredName":"Myelodysplastic Syndrome And/Or Chronic Myeloproliferative Disease or Disorder Classification Type","preferredDefinition":"A description of myelodysplastic syndrome and/or chronic myeloproliferative disease classification.","longName":"2738439v1.0:2738441v1.2","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2738439","version":"1","preferredName":"Myelodysplastic Syndrome And/Or Chronic Myeloproliferative Disease or Disorder Classification","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001)_Used to indicate that either or both of two items or options may be valid._Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"MDS_MPS_CLS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2757131","version":"1","preferredName":"MDS And/Or Chronic Myeloproliferative Disorder Disease or Disorder","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003:Used to indicate that either or both of two items or options:Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults.  -- 2003:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","longName":"C3247:C48928:C4345:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F1499FD-0675-4E1A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-07","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-06-07","modifiedBy":"ONEDATA","dateModified":"2008-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-EBCA-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-31","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2738441","version":"1.2","preferredName":"Myelodysplastic Syndrome And/Or Chronic Myeloproliferative Disorder Classification Type","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001)_Used to indicate that either or both of two items or options may be valid._Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._Type; a subdivision of a particular kind of thing.","longName":"2738441v1.2","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Atypical chronic myeloid leukemia, Ph unknown/bcr unknown (CML, NOS)","valueDescription":"Ph Unknown/BCR Unknown Atypical Chronic Myeloid Leukemia","ValueMeaning":{"publicId":"3928691","version":"1","preferredName":"Ph Unknown/BCR Unknown Atypical Chronic Myeloid Leukemia","longName":"3928691","preferredDefinition":"Philadelphia chromosome adnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not tested; therefore it is not known whether it is present or not. : A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia.  The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph Unknown/BCR Unknown","conceptCode":"C70628","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not tested; therefore it is not known whether it is present or not.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Atypical Chronic Myeloid Leukemia","conceptCode":"C3519","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C0471-090F-638E-E040-BB89AD436B99","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC43-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Atypical chronic myeloid leukemia, Ph unknown/bcr- (CML, NOS)","valueDescription":"Ph Unknown/BCR- Atypical Chronic Myeloid Leukemia","ValueMeaning":{"publicId":"3928692","version":"1","preferredName":"Ph Unknown/BCR- Atypical Chronic Myeloid Leukemia","longName":"3928692","preferredDefinition":"Philadelphia chromosome adnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not found. : A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia.  The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph Unknown/BCR-","conceptCode":"C70627","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not; bcr/abl gene rearrangement was not found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Atypical Chronic Myeloid Leukemia","conceptCode":"C3519","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C0471-0931-638E-E040-BB89AD436B99","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC4D-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Atypical chronic myeloid leukemia, Ph-/bcr unknown (CML, NOS)","valueDescription":"Ph-/BCR Unknown Atypical Chronic Myeloid Leukemia","ValueMeaning":{"publicId":"3928693","version":"1","preferredName":"Ph-/BCR Unknown Atypical Chronic Myeloid Leukemia","longName":"3928693","preferredDefinition":"Philadelphia chromosome adnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not. : A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia.  The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph-/BCR Unknown","conceptCode":"C70630","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not tested; therefore it is not known if present or not.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Atypical Chronic Myeloid Leukemia","conceptCode":"C3519","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C0471-0953-638E-E040-BB89AD436B99","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC57-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Myelodysplastic / myeloproliferative neoplasm, unclassifiable","valueDescription":"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable","ValueMeaning":{"publicId":"4130276","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable","longName":"4130276","preferredDefinition":"This entity includes cases that have clinical, laboratory, and morphologic features that support the diagnosis of both a myelodysplastic syndrome and a myeloproliferative neoplasm, but do not meet the criteria for any of the other entities included in the myelodysplastic/myeloproliferative neoplasm category.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","conceptCode":"C27780","definition":"A myelodysplastic/myeloproliferative neoplasm that does not meet the criteria of other myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms. It is associated with cytopenia, blasts less than 20% in bone marrow and peripheral blood, thrombocytosis, and absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F18569AC-00DE-4E6D-E040-BB89AD437CF4","latestVersionIndicator":"Yes","beginDate":"2014-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FD4D-2AB6-E050-BB89AD437F1B","beginDate":"2015-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Atypical chronic myeloid leukemia, Ph-/bcr/abl- (CML, NOS)","valueDescription":"Ph -/BCR-ABL- Atypical Chronic Myeloid Leukemia","ValueMeaning":{"publicId":"3928672","version":"1","preferredName":"Ph -/BCR-ABL- Atypical Chronic Myeloid Leukemia","longName":"3928672","preferredDefinition":"Philadelphia chromosome adnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not found. : A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia.  The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ph -/BCR-ABL-","conceptCode":"C70629","definition":"Philadelphia chromosome abnormality; t(9;22)(q34;q11) was not found; bcr/abl gene rearrangement was not found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Atypical Chronic Myeloid Leukemia","conceptCode":"C3519","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E97C0471-08E5-638E-E040-BB89AD436B99","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-24","modifiedBy":"ONEDATA","dateModified":"2013-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC61-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome with isolated del(5q) (5q- syndrome)","valueDescription":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","ValueMeaning":{"publicId":"2738446","version":"1","preferredName":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","longName":"2738446","preferredDefinition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with normal to increased, often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with del(5q)","conceptCode":"C6867","definition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-ED8B-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC6B-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Transformed to AML","valueDescription":"Conversion Acute Myeloid Leukemia","ValueMeaning":{"publicId":"3927451","version":"1","preferredName":"Conversion Acute Myeloid Leukemia","longName":"3927451","preferredDefinition":"The act of changing the nature, form, function, or purpose of something to another.: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conversion","conceptCode":"C52566","definition":"The act of changing the nature, form, function, or purpose of something to another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96A8E65-4091-B964-E040-BB89AD437DDF","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC75-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Chronic eosinophilic leukemia, NOS","valueDescription":"Chronic Eosinophilic Leukemia","ValueMeaning":{"publicId":"2738445","version":"1","preferredName":"Chronic Eosinophilic Leukemia","longName":"2738445","preferredDefinition":"A rare chronic myeloproliferative disorder characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","conceptCode":"C4563","definition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-ED4F-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC7F-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Primary myelofibrosis (includes chronic idiopathic myelofibrosis (CIMF), angiogenic myeloid metaplasia (AMM), myelofibrosis/sclerosis with myeloid metaplasia (MMM), idiopathic myelofibrosis)","valueDescription":"Primary Myelofibrosis","ValueMeaning":{"publicId":"3323718","version":"1","preferredName":"Primary Myelofibrosis","longName":"3323718","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. The cause is unknown. The median survival time is 3-5 years from diagnosis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Myelofibrosis","conceptCode":"C2862","definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-8290-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC89-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Chronic myelomonocytic leukemia (CMMoL)","valueDescription":"Chronic Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2771865","version":"1","preferredName":"Chronic Myelomonocytic Leukemia","longName":"2771865","preferredDefinition":"A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54342348-5E2F-4602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC93-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Chronic neutrophilic leukemia","valueDescription":"Chronic Neutrophilic Leukemia","ValueMeaning":{"publicId":"2837958","version":"1","preferredName":"Chronic Neutrophilic Leukemia","longName":"2837958","preferredDefinition":"A rare chronic myeloproliferative disorder characterised by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Neutrophilic Leukemia","conceptCode":"C3179","definition":"A rare chronic myeloproliferative neoplasm characterized by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CECC-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FC9D-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Essential thrombocythemia (includes primary thrombocytosis, idiopathic thrombocytosis, hemorrhagic thrombocythemia)","valueDescription":"Essential Thrombocythemia","ValueMeaning":{"publicId":"2838061","version":"1","preferredName":"Essential Thrombocythemia","longName":"2838061","preferredDefinition":"A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage.  The cause is unknown.  Median survival times of 10-15 years are commonly reported.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Thrombocythemia","conceptCode":"C3407","definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF56-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FCA7-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Polycythemia vera (PCV)","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2559822","version":"1","preferredName":"Polycythemia Vera","longName":"2559822","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6BB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FCB1-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Juvenile myelomonocytic leukemia (JMML/JCML) (no evidence of Ph1 or BCR/ABL)","valueDescription":"Juvenile Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2559013","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2559013","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B392-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FCBB-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Refractory anemia with excess blasts-1 (RAEB-1)","valueDescription":"RAEB-1","ValueMeaning":{"publicId":"2582031","version":"1","preferredName":"RAEB-1","longName":"2582031","preferredDefinition":"A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood.  Approximately 25% of cases progress to an acute leukemia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts-1","conceptCode":"C7167","definition":"A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood.  Approximately 25% of cases progress to an acute leukemia. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":"Fixed the less than symbol in System Generated Value Meaning Description by removing and replacing the associated concept. dbw Dec-20-2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FCCF-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Refractory anemia with excess blasts-2 (RAEB-2)","valueDescription":"RAEB-2","ValueMeaning":{"publicId":"2582030","version":"1","preferredName":"RAEB-2","longName":"2582030","preferredDefinition":"A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood. Approximately 33% of cases progress to acute leukemia.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","conceptCode":"C7168","definition":"A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":"Refreshed concept association to pick up correct symbol instead of  <. 12.15.17 Updated definition to match current NCIt as requested by NMDP. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FCD9-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Refractory anemia with ringed sideroblasts (RARS)","valueDescription":"Refractory Anemia with Ringed Sideroblasts","ValueMeaning":{"publicId":"2771857","version":"1","preferredName":"Refractory Anemia with Ringed Sideroblasts","longName":"2771857","preferredDefinition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ringed sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain.  It occurs primarily in older individuals.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Ring Sideroblasts","conceptCode":"C4036","definition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF42-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FCE3-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Refractory cytopenia with multilineage dysplasia (RCMD)","valueDescription":"Refractory Cytopenia with Multilineage Dysplasia","ValueMeaning":{"publicId":"2771858","version":"1","preferredName":"Refractory Cytopenia with Multilineage Dysplasia","longName":"2771858","preferredDefinition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines.  A minority of cases progress to acute myeloid leukemia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia","conceptCode":"C8574","definition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF67-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FCED-2AB6-E050-BB89AD437F1B","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Myeloproliferative neoplasm (MPN), unclassifiable","valueDescription":"Chronic Myeloproliferative Disease, Unclassifiable","ValueMeaning":{"publicId":"3249791","version":"1","preferredName":"Chronic Myeloproliferative Disease, Unclassifiable","longName":"3249791","preferredDefinition":"This subgroup of chronic myeloproliferative disorders includes cases which do not meet the morphologic criteria of any of the defined chronic myeloproliferative disorders, or which have characteristics that overlap at least two of the chronic myeloproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm, Not Otherwise Specified","conceptCode":"C27350","definition":"This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6DC37F6-CFCC-75B6-E040-BB89AD430517","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FCF7-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome (MDS), unclassifiable","valueDescription":"Myelodysplastic Syndrome, Unclassifiable","ValueMeaning":{"publicId":"2771859","version":"1","preferredName":"Myelodysplastic Syndrome, Unclassifiable","longName":"2771859","preferredDefinition":"A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood;  2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome, Unclassifiable","conceptCode":"C8648","definition":"A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood; 2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AFB9-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FD01-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Childhood myelodysplastic syndrome (Refractory cytopenia of childhood (RCC))","valueDescription":"Childhood Myelodysplastic Syndrome","ValueMeaning":{"publicId":"3927432","version":"1","preferredName":"Childhood Myelodysplastic Syndrome","longName":"3927432","preferredDefinition":"An uncommon hematologic malignancy occurring during childhood. Many of the morphologic, immunophenotypic, and genetic changes seen in adult myelodysplastic syndromes are also observed in the childhood variants of the disease. Children present with neutropenia and thrombocytopenia more often than adults, and bone marrow hypocellularity is more often seen in children than adults.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Childhood Myelodysplastic Syndrome","conceptCode":"C68744","definition":"An uncommon hematologic malignancy occurring during childhood. Many of the morphologic, immunophenotypic, and genetic changes seen in adult myelodysplastic syndromes are also observed in the childhood variants of the disease. Children present with neutropenia and thrombocytopenia more often than adults, and bone marrow hypocellularity is more often seen in children than adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E969AD1A-AFA9-B9EE-E040-BB89AD432F0D","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FD0B-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory anemia (RA))","valueDescription":"Refractory Cytopenia with Unilineage Dysplasia","ValueMeaning":{"publicId":"3251318","version":"1","preferredName":"Refractory Cytopenia with Unilineage Dysplasia","longName":"3251318","preferredDefinition":"A myelodysplastic syndrome characterized by dysplastic changes involving only one myeloid cell lineage in the bone marrow. It primarily affects older adults and includes refractory anemia, refractory neutropenia, and refractory thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome, Not Otherwise Specified with Single Lineage Dysplasia","conceptCode":"C82591","definition":"A myelodysplastic syndrome characterized by dysplastic changes involving only one myeloid cell lineage in the bone marrow.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A757E577-0B9A-B648-E040-BB89AD434049","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FD15-2AB6-E050-BB89AD437F1B","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Chronic MPS disorder, not otherwise specified","valueDescription":"Not Otherwise Specified Myeloproliferative Neoplasm","ValueMeaning":{"publicId":"4718151","version":"1","preferredName":"Not Otherwise Specified Myeloproliferative Neoplasm","longName":"4718151","preferredDefinition":"Not characterized in any other way.: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EF8247F-14E0-5CF8-E050-BB89AD43484A","latestVersionIndicator":"Yes","beginDate":"2015-02-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FD1F-2AB6-E050-BB89AD437F1B","beginDate":"2015-02-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Refractory anemia with ringed sideroblasts with dysplasia (RCMD-RS)","valueDescription":"Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts","ValueMeaning":{"publicId":"2738442","version":"1","preferredName":"Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts","longName":"2738442","preferredDefinition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia, dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines, and 15% or more ringed sideroblasts in the bone marrow.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia","conceptCode":"C27726","definition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia, dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines, and 15% or more ring sideroblasts in the bone marrow.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-EC12-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FD29-2AB6-E050-BB89AD437F1B","beginDate":"2015-02-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Refractory anemia (RA)","valueDescription":"Refractory Anemia","ValueMeaning":{"publicId":"2771856","version":"1","preferredName":"Refractory Anemia","longName":"2771856","preferredDefinition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Anemia","conceptCode":"C2872","definition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF1D-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10A342EF-FD33-2AB6-E050-BB89AD437F1B","beginDate":"2015-02-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"ONEDATA","dateModified":"2015-03-06","deletedIndicator":"No"},{"value":"Atypical chronic myeloid leukemia (aCML), BCR-ABL1-","valueDescription":"Atypical Chronic Myeloid Leukemia","ValueMeaning":{"publicId":"2837831","version":"1","preferredName":"Atypical Chronic Myeloid Leukemia","longName":"2837831","preferredDefinition":"A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia.  The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Chronic Myeloid Leukemia","conceptCode":"C3519","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-481E-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F9DAF93-4ED8-0A93-E053-F662850A5D30","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"ONEDATA","dateModified":"2017-12-05","deletedIndicator":"No"},{"value":"Myeloid / lymphoid neoplasms with PCM1-JAK2","valueDescription":"Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1-JAK2","ValueMeaning":{"publicId":"6037339","version":"1","preferredName":"Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1-JAK2","longName":"6037339","preferredDefinition":"Rare myeloid neoplasms characterized by eosinophilia, bone marrow findings of left-shifted erythroid predominance, lymphoid aggregates, and often myelofibrosis, and the detection of t(8;9)(p22;p24.1) and PCM1-JAK2 fusion gene. Rare cases present as T- or B-acute lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid/Lymphoid Neoplasms with JAK2 Rearrangement","conceptCode":"C129853","definition":"Hematologic neoplasms characterized by the presence of t(8;9)(p22;p24.1) that results in PCM1-JAK2 fusion gene expression. It is associated with eosinophilia, bone marrow findings of left-shifted erythroid predominance, lymphoid aggregates, and often myelofibrosis. Rare cases present as T- or B-acute lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4EE5-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F9DAF93-4EFE-0A93-E053-F662850A5D30","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"ONEDATA","dateModified":"2017-12-05","deletedIndicator":"No"},{"value":"Myeloid / lymphoid neoplasms with PDGFRB rearrangement","valueDescription":"Myeloid and Lymphoid Neoplasms with PDGFRB Rearrangement","ValueMeaning":{"publicId":"6037343","version":"1","preferredName":"Myeloid and Lymphoid Neoplasms with PDGFRB Rearrangement","longName":"6037343","preferredDefinition":"Myeloid and rarely lymphoid neoplasms characterized by the rearrangement of the PDGFRB gene, most often resulting in the formation of ETV6-PDGFRB fusion transcripts. Patients usually present with chronic myelomonocytic leukemia and less often with atypical chronic myeloid leukemia, or chronic eosinophilic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement","conceptCode":"C84276","definition":"Myeloid and rarely lymphoid neoplasms characterized by the rearrangement of the PDGFRB gene, most often resulting in the formation of ETV6-PDGFRB fusion transcripts. Patients usually present with chronic myelomonocytic leukemia and less often with atypical chronic myeloid leukemia, or chronic eosinophilic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4F31-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F9DAF93-4F4A-0A93-E053-F662850A5D30","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"ONEDATA","dateModified":"2017-12-05","deletedIndicator":"No"},{"value":"Myeloid / lymphoid neoplasms with PDGFRA rearrangement","valueDescription":"Myeloid and Lymphoid Neoplasms with PDGFRA Rearrangement","ValueMeaning":{"publicId":"6037345","version":"1","preferredName":"Myeloid and Lymphoid Neoplasms with PDGFRA Rearrangement","longName":"6037345","preferredDefinition":"Hematologic neoplasms characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts. Patients usually present with chronic eosinophilic leukemia, and less often with acute myeloid leukemia or T-lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement","conceptCode":"C84275","definition":"Hematologic neoplasms characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts. Patients usually present with chronic eosinophilic leukemia, and less often with acute myeloid leukemia or T-lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4F57-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F9DAF93-4F70-0A93-E053-F662850A5D30","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"ONEDATA","dateModified":"2017-12-05","deletedIndicator":"No"},{"value":"Mastocytosis","valueDescription":"Mastocytosis","ValueMeaning":{"publicId":"3210971","version":"1","preferredName":"Mastocytosis","longName":"3210971","preferredDefinition":"A clonal myeloproliferative neoplasm characterized by the proliferation and accumulation of neoplastic mast cells in one or multiple organs or organ systems.  It is a heterogeneous group of neoplasms, ranging from cutaneous proliferations which may regress spontaneously, to aggressive neoplasms associated with organ failure and short survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mastocytosis","conceptCode":"C84269","definition":"A clonal myeloproliferative neoplasm characterized by the proliferation and accumulation of neoplastic mast cells in one or multiple organs or organ systems. It is a heterogeneous group of neoplasms, ranging from cutaneous proliferations which may regress spontaneously, to aggressive neoplasms associated with organ failure and short survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BBBC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5F9DAF93-4F7A-0A93-E053-F662850A5D30","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"ONEDATA","dateModified":"2017-12-05","deletedIndicator":"No"},{"value":"Myeloid / lymphoid neoplasms with FGFR1 rearrangement","valueDescription":"Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement","ValueMeaning":{"publicId":"6037341","version":"1","preferredName":"Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement","longName":"6037341","preferredDefinition":"Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement","conceptCode":"C84277","definition":"Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4F0B-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5FB02B44-76F2-6F76-E053-F662850ADE6E","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-06","modifiedBy":"ONEDATA","dateModified":"2017-12-06","deletedIndicator":"No"},{"value":"MDS / MPN with ring sideroblasts and thrombocytosis (MDS / MPN-RS-T)","valueDescription":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis","ValueMeaning":{"publicId":"6037337","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis","longName":"6037337","preferredDefinition":"A myelodysplastic/myeloproliferative neoplasm with morphologic and clinical characteristics of refractory anemia with ring sideroblasts, marked thrombocytosis, and abnormal megakaryocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified","conceptCode":"C82616","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by marked thrombocytosis, anemia, erythroid lineage dysplasia, presence or absence of multilineage dysplasia, 15% or more ring sideroblasts, blasts less than 5% in bone marrow and less than 1% in peripheral blood, absence of BCR/ABL fusion, absence of SF3B1 mutation, absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and no history of other myelodysplastic/myeloproliferative neoplasms or myeloproliferative neoplasms and myelodysplastic syndromes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4EAB-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60137ADA-1346-3B23-E053-F662850A851A","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-11","modifiedBy":"ONEDATA","dateModified":"2017-12-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2757132","version":"1","preferredName":"MDS And/Or Chronic Myeloproliferative Disorder Classification Type","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003:Used to indicate that either or both of two items or options:Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults.  -- 2003:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:Type; a subdivision of a particular kind of thing.","longName":"C3247:C48928:C4345:C25161:C252","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F1499FD-068F-4E1A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-07","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-06-07","modifiedBy":"ONEDATA","dateModified":"2008-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A342EF-FC2D-2AB6-E050-BB89AD437F1B","latestVersionIndicator":"Yes","beginDate":"2015-03-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"GDEEN","dateModified":"2022-07-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964931","version":"1","longName":"2014r1: MDS Pre-HSCT Data","context":"NHLBI"},{"publicId":"2964924","version":"1","longName":"2400r1: Pre-TED","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"MDSpre_assess_diag_mds_mpn_subtype","type":"NMDP_FN","context":"NHLBI"},{"name":"MDSpre_transform_mds_mpn_post_transform_subtype","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"pre_ted_who_mds_mps_dx","type":"NMDP_FN","context":"NHLBI"},{"name":"pre_ted_who_mds_mps_hsct","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_mds_mpn_alt_class","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_mds_mpn_alt_subtype","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_mds_mpn_post_transform_class","type":"NMDP_FN","context":"NHLBI"},{"name":"PreTed_prime_dis_hct_mds_mpn_post_transform_subtyp","type":"NMDP_FN","context":"NHLBI"},{"name":"mds_base_diag_subtype","type":"NMDP_FN","context":"NHLBI"},{"name":"mds_base_prep_trnf_sub_sp","type":"NMDP_FN","context":"NHLBI"},{"name":"CPRE_ICT_mds_mpn_alt_subtype","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_MDS_mds_mpn_alt_subtype","type":"NMDP_FN","context":"NHLBI"},{"name":"TDIS_MDS_mds_mpn_pst_tr_subtyp","type":"NMDP_FN","context":"NHLBI"},{"name":"MDS_CMP_DS_CLASS_TYP","type":"C3D Name","context":"CCR"}],"ReferenceDocuments":[{"name":"What was the MDS / MPN subtype?","type":"Alternate Question Text","description":"What was the MDS / MPN subtype?","url":null,"context":"NHLBI"},{"name":"What was the MDS / MPN subtype?","type":"Application Standard Question Text","description":"What was the MDS / MPN subtype?","url":null,"context":"NHLBI"},{"name":"What was the MDS / MPS subtype?","type":"Alternate Question Text","description":"What was the MDS / MPS subtype?","url":null,"context":"NHLBI"},{"name":"What was the myelodysplastic","type":"Preferred Question Text","description":"What was the myelodysplastic syndrome or myeloproliferative disease classification?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2738448","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.value(ANY=>CD).code","url":null,"context":"NHLBI"},{"name":"What was the MDS / MPN classification at diagnosis?","type":"Alternate Question Text","description":"What was the MDS / MPN classification at diagnosis?","url":null,"context":"NHLBI"},{"name":"Specify the MDS / MPN classification after transformation:","type":"Alternate Question Text","description":"Specify the MDS / MPN classification after transformation:","url":null,"context":"NHLBI"},{"name":"Specify the MDS / MPN subtype","type":"Alternate Question Text","description":"Specify the MDS / MPN subtype","url":null,"context":"NHLBI"},{"name":"What was the MDS / MPN subtype at diagnosis?","type":"Alternate Question Text","description":"What was the MDS / MPN subtype at diagnosis?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A342EF-FD5C-2AB6-E050-BB89AD437F1B","latestVersionIndicator":"Yes","beginDate":"2015-03-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-06","modifiedBy":"GDEEN","dateModified":"2022-07-12","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}